Prognostic Values of Inflammation-based Indices in Gastric Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the prognostic values of preoperative inflammation-based indices in patients undergoing potentially curative resection of gastric cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery

NCT06023966

Predictive Cancer Model Hepatic Metastasis Gastric Cancer

COMPLETED

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study

NCT03121729

Gastric Cancer

UNKNOWN NA

Preoperative Nutritional Status and Postoperative Outcomes in Colorectal Cancer

NCT06016829

Colorectal Cancer

COMPLETED

Perioperative Nutrition in Upper Gastrointestinal (GI) Cancer Surgery

NCT00560846

Stomach Neoplasms Esophageal Neoplasms

TERMINATED NA

Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial

NCT06468969

Gastric Cancer Total Gastrectomy Postoperative Care +2 more

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gastric cancer is one of the most common and deadly cancers worldwide. Based on GLOBOCAN 2018 data, it is the fifth most common malignancy and the third leading cause of cancer deaths, with an estimated 783,000 deaths in 2018. Despite advances in diagnosis and management strategies, outcomes for patients diagnosed with gastric cancer still remain poor and the five-year survival is approximately %20. In addition, there is marked heterogeneity in the duration of survival among patients. Hence, there are increasing research efforts towards the identification of possible predictive clinical, pathological, or biologic factors to determine more accurate patient stratification, which will improve clinical decision-making and possibly contribute to more rational study design and analysis. Systemic inflammation is known to play a crucial role in the pathogenesis, development, and progression of cancer. Preoperative inflammation-based indices, such as the Glasgow prognostic score (GPS), modified Glasgow prognostic score (mGPS), neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), prognostic index (PI), prognostic nutritional index (PNI), CRP/albumin ratio, systemic inflammation score (SIS), modified systemic inflammation score (mSIS), have been found to have potential prognostic values in various cancer. Previous studies have suggested that several of these scoring systems may have a role in predicting survival in patients with upper gastrointestinal cancer. These scores are all derived from blood tests that are already routinely performed in clinical practice and thus have the potential to offer valuable additional information that may help to guide patient management. This study aims to evaluate the prognostic values of preoperative inflammation-based indices in patients undergoing potentially curative resection of gastric cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (high marker)

Patients with elevated serum markers

Gastrectomy

Intervention Type PROCEDURE

Any type of gastrectomy for gastric cancer

Group 2 (normal marker)

Patients with normal value of serum markers

Gastrectomy

Intervention Type PROCEDURE

Any type of gastrectomy for gastric cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gastrectomy

Any type of gastrectomy for gastric cancer

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18 who underwent a surgical procedure for gastric cancer

Exclusion Criteria

* Patients \< 18 years of age
* Patients with no routine blood examination before surgery or incomplete medical records
* Patients followed up less than 3 months
* Patients with additional malignancy
* Patients having tumors that invading adjacent organs
* Patients with adjacent or distant metastasis
* Patients receiving neoadjuvant therapy (chemo- or radiotherapy)
* Patients with previous malignancy history
* Patients with a clinical evidence of infection
* Patients with a history of preoperative use of anti-inflammatory drugs or immunosuppressive treatment
* Patients with a history of chronic inflammatory disease or autoimmune disease
* Patients who underwent emergency surgical resection
* Patients who have undergone R1/R2 resection or those with positive peripheral margins
* Patients with missing data on follow-up

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No